DIAMEDICA THERAPEUTICS INC (DMAC) Stock Price & Overview
NASDAQ:DMAC • CA25253X2077
Current stock price
The current stock price of DMAC is 6.48 USD. Today DMAC is up by 0.93%. In the past month the price decreased by -14.62%. In the past year, price increased by 85.14%.
DMAC Key Statistics
- Market Cap
- 337.478M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.70
- Dividend Yield
- N/A
DMAC Stock Performance
DMAC Stock Chart
DMAC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to DMAC. When comparing the yearly performance of all stocks, DMAC is one of the better performing stocks in the market, outperforming 84.11% of all stocks.
DMAC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DMAC. While DMAC seems to be doing ok healthwise, there are quite some concerns on its profitability.
DMAC Earnings
DMAC Forecast & Estimates
11 analysts have analysed DMAC and the average price target is 15.81 USD. This implies a price increase of 143.98% is expected in the next year compared to the current price of 6.48.
DMAC Groups
Sector & Classification
DMAC Financial Highlights
Over the last trailing twelve months DMAC reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS decreased by -16.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.96% | ||
| ROE | -61.85% | ||
| Debt/Equity | 0 |
DMAC Ownership
DMAC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DMAC
Company Profile
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 27 full-time employees. The company went IPO on 2008-01-04. The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
Company Info
IPO: 2008-01-04
DIAMEDICA THERAPEUTICS INC
301 Carlson Parkway, Suite 210
Minneapolis MINNESOTA 55447 US
CEO: Rick Pauls
Employees: 28
Phone: 17634965454
DIAMEDICA THERAPEUTICS INC / DMAC FAQ
What does DIAMEDICA THERAPEUTICS INC do?
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 27 full-time employees. The company went IPO on 2008-01-04. The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
What is the current price of DMAC stock?
The current stock price of DMAC is 6.48 USD. The price increased by 0.93% in the last trading session.
Does DIAMEDICA THERAPEUTICS INC pay dividends?
DMAC does not pay a dividend.
What is the ChartMill technical and fundamental rating of DMAC stock?
DMAC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does DIAMEDICA THERAPEUTICS INC belong to?
DIAMEDICA THERAPEUTICS INC (DMAC) operates in the Health Care sector and the Biotechnology industry.
Would investing in DIAMEDICA THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DMAC.